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Abstract
Background: In early 2001 Australia experienced a sudden and unexpected disruption to heroin
availability, know as the 'heroin shortage'. This 'shortage has been linked to a decrease in needle
and syringe output and therefore possibly a reduction in injecting drug use. We aimed to examine
changes, if any, in blood-borne viral infections and presentations for injecting related problems
related to injecting drug use following the reduction heroin availability in Australia, in the context
of widespread harm reduction measures.
Methods: Time series analysis of State level databases on HIV, hepatitis B, hepatitis C notifications
and hospital and emergency department data. Examination of changes in HIV, hepatitis B, hepatitis
C notifications and hospital and emergency department admissions for injection-related problems
following the onset of the heroin shortage; non-parametric curve-fitting of number of hepatitis C
notifications among those aged 15–19 years.
Results: There were no changes observed in hospital visits for injection-related problems. There
was no change related to the onset heroin shortage in the number of hepatitis C notifications
among persons aged 15–19 years, but HCV notifications have subsequently decreased in this group.
No change occurred in HIV and hepatitis B notifications.
Conclusion: A marked reduction in heroin supply resulted in no increase in injection-related harm
at the community level. However, a delayed decrease in HCV notifications among young people
may be related. These changes occurred in a setting with widespread, publicly funded harm
reduction initiatives.
Background
Injecting drug use is an important risk factor for the trans-
mission of blood-borne viral infections (BBVI) such as the
human immunodeficiency virus (HIV) and the hepatitis C
virus (HCV) [1]. Harm reduction strategies such as needle
and syringe programs have been instrumental in main-
taining low HIV prevalence among injecting drug users
(IDU) in settings where they were implemented early [2],
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such as Australia [3,4]. Reducing the prevalence and inci-
dence of HCV, however, has proved more challenging
with continuing high prevalence among injecting drug
users in Australia [5,6] and elsewhere [7,8] and high inci-
dence among young injectors [9]. IDU are also subject to
increased risk of other injection-related problems such as
abscesses and thromboses [10,11].
Caulkins has suggested that illicit drug-related harms are
influenced by drug price [12]. A significant relationship
was found between drug prices, and mentions of cocaine
and heroin in United States Emergency Departments,
whereby admissions increased as drug prices decreased
[12]. These findings raise the question: Would injecting-
related harms including BBVI decrease  if drug prices
increased and availability decreased [13]? The answer to
this question, until now, has been based upon theory
rather than evidence, because sharp reductions in drug
supply have rarely occurred. In this paper, we take advan-
tage of recent changes in the Australian heroin market to
answer this question empirically.
In early 2001, there were consistent reports of a dramatic
decline in the availability of heroin in New South Wales
(NSW) [14,15], where previously heroin had been readily
available at historically low price and high purity [16].
Australia's Illicit Drug Reporting System revealed a reduc-
tion in heroin supply across Australia, reflected by
reduced purity and availability, and a marked increase in
price [17]. This 'heroin shortage' was most severe from
January to April 2001 [18]. The market began to stabilise
after this date but heroin availability has not returned to
pre-shortage levels, and the heroin market in Australia
appears to have been altered in structure [18].
The reduced heroin supply resulted in at least some
former primary heroin users substituting a range of other
drug classes for heroin during the shortage, in particular
cocaine [15,19,20]. Changes in the heroin market was
also associated with a significant decrease in the distribu-
tion of needles and syringes, a proxy measure for injecting
drug use [21].
This change is important because increased prevalence of
cocaine injection has been associated with a number of
adverse consequences. The HIV outbreak during the mid
1990s in Vancouver has been attributed in part to
increased cocaine injection [22]. It has since been found
to be an independent predictor of HIV infection [23] and
related to high levels of Emergency Department use for
drug related problems, most notably soft tissue infection
[24]. Given that heroin use has driven the hepatitis C epi-
demic in Australia, it is unclear what impact changes in
patterns of drug use will have on the epidemic [25].
An increase in benzodiazepine injection was also reported
to occur at the time of the shortage [19]. Benzodiazepine
injection is associated with a range of harms, including
soft tissue damage and increased BBVI risk [26,27]. Harms
such as these were reported in qualitative accounts of the
shortage by both IDU and key informants.
These changes in drug availability and patterns of inject-
ing drug use occurred in a setting in which harm reduction
strategies were widely used. Publicly funded NSPs were
introduced to Australia in 1987 [28], and methadone
maintenance programs which were established in the
1970s were significantly expanded in 1985 and again in
1999 [29]. More recently, a Medically Supervised Injecting
Centre was trialled in one of the key NSW drug markets
[30]. Although needle and syringe sharing continues to be
reported in Australia, the available evidence suggests that
the prevalence of this behaviour has remained stable at
15–20% sharing in the past month [31].
Given these changes in drug use in an established harm
reduction setting, this study aimed to examine population
level changes in harms associated with injecting drug use,
such as HCV, HIV and hepatitis B (HBV) that occurred
after the change in heroin supply in NSW, the State con-
taining Australia's largest heroin markets [32]. Specifi-
cally, the study examined:
1. Changes, if any, in the number of notifications of BBVI
cases including the hepatitis B virus (HBV), HCV and HIV.
In particular trends in HCV notifications among young
persons, who are at greatest risk of infection [9,33] and
among whom prevalence provides a reasonable approxi-
mation of incidence were examined; and
2. Changes, if any, in ED and hospital data on presenta-
tions for injection-related problems (possibly as a result
of the increased use of other drugs such as cocaine and
benzodiazepines).
Methods
Data
New cases of HCV, HBV and HIV must be notified by
either doctor or laboratory to the State Health Depart-
ment where they are recorded in the Notifiable Diseases
Database and the HIV/AIDS database. Notification of
these infections is mandatory in Australia, thus all labora-
tories are legally obligated to notify all positive results.
Notification includes date of birth and detailed name
codes, thereby reducing duplicate notifications. De-iden-
tified data were retrieved from these databases on the
number of individuals diagnosed by age and gender.
Monthly data by date of diagnosis on diagnoses were
available from 1997.BMC Public Health 2005, 5:84 http://www.biomedcentral.com/1471-2458/5/84
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Although not all HBV and HIV notifications are due to
injecting drug use (indeed in Australia, very few HIV infec-
tions are likely to be [3]), this is true across all time points
examined, and there is no extraneous reason to believe
that this pattern would have changed over the period
examined. In the case of HCV, more than 90% of such
cases occur through injecting drug use [34], thus any
changes in these data are very probably directly related to
injecting drug use.
Due to the often asymptomatic nature of HCV, not all
new diagnoses represent acute or newly acquired infec-
tions. Given this, notifications among young IDU are con-
sidered those most likely to reflect new hepatitis C
infections, or incident cases. Large proportions of IDU
(>60%) report recent HCV testing [31]. Thus data on HCV
notification among young people was analysed
separately.
Diagnostic information on persons presenting to the
NSW hospital EDs is recorded at the time of presentation
and is coded using the International Classification of Dis-
eases, 9th Revision (ICD_9). The NSW Emergency Depart-
ment Collection is a database of information collected
from approximately a third of NSW EDs. Because these are
mostly the larger EDs in NSW, the Collection represents
approximately two thirds of all NSW emergency patients.
The following codes were used to examine injection-
related problems: unspecified septicaemia (038.9); acute
and subacute endocarditis (421.0); other peripheral vas-
cular disease (443.9); phlebitis and thrombophlebitis
(451.0); other venous embolism and thrombosis (458.8);
cellulitis and abscess (681.00, 681.10, 682.0–9); other
local infections of skin and subcutaneous tissue (686.9)
and chronic ulcer of skin (707.1, 707.9).
Data analysis
Ideally time series of the sort presented here would be
analysed using intervention time series models, which
allow estimation of the effect of posited interventions in
the series after adjusting for the relationships which exist
between different values over time in many time series
data (serial dependence). For HCV notifications amongst
15–19 year olds, the intervention model time series was
not appropriate because the series showed different
behaviour in different time periods, so a loess smoother
[35] was fitted to this data series using S-Plus 6.1. Such a
smoother fits a line to the data using a series of linear
regressions fitted in a small neighbourhood of points. For
this data the size of this neighbourhood (the span) was
estimated using Generalised Cross Validation [36]. Such
methods enable the shape of the modelled data to be esti-
mated based only on the data, and avoid subjective deci-
sions about details of the plot, such as the point at which
periods of different behaviour occur (changes in slope) or
the precise point of onset of sudden changes in level
(steps) [36]. This enabled the researchers to avoid making,
for example, subjective judgements about exactly when
HCV notifications began to decline. Other time series had
small counts and no formal time series analysis was con-
ducted – these series were inspected for signs of large-scale
changes at the point of the heroin shortage.
Results
Blood borne viral infections (BBVIs)
The possibility of changes in BBVIs was examined using
data on NSW notifications of HBV, HCV and HIV infec-
tion. There were no apparent differences in the overall
number of total notifications following the onset of the
shortage for HIV, HCV or HBV (Figure 1). However, the
number of HCV and HBV notifications for persons aged
15–19 years, the groups most likely to be effected, were
examined (Figure 2). Cross-correlation functions indi-
cated that there was no significant relationship between
those functions which describe the heroin shortage and
the HCV notifications data at plausible positive lags. A
loess smoother (span = 0.75) was fitted to the HCV noti-
fication data in order to describe the general structure of
the series (Figure 3), and indicated that the series peaked
several months before the onset of the heroin shortage,
with a downward trend in the series after this point.
There is no evidence that this downward trend changed at
the time of the heroin shortage or that there were transient
non-random increases in the series after the shortage.
Unfortunately the series was not amenable to ARIMA
methods and more informative analysis could not be con-
ducted in the absence of plausible evidence from cross-
correlation functions of a shortage effect on the series (as
described above).
Injection-related problems
Figure 4 shows the number of ED admissions and hospital
separations where injection-related problems were noted,
from 1997–2003. No formal time series was conducted
due to the small numbers of such admissions noted each
month. No noticeable increase occurred following the
onset of the shortage.
Discussion
This study found no increase in notifications for HIV,
HCV or HBV following the reduction in heroin supply.
Given that only a proportion of HIV and HBV cases are
attributable to injecting drug use, this is perhaps not sur-
prising HIV and HBV. However, the clear reduction in
HCV cases among those aged 15–19 years, commencing
slightly before the onset of the reduction in heroin supply,
was consistent with declines in other indicators of heroin-
related harm in the community, including a State-wide
28% reduction in needle and syringe distribution [21]; aBMC Public Health 2005, 5:84 http://www.biomedcentral.com/1471-2458/5/84
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63% decrease in ambulance callouts, a 40% decrease in
emergency department admissions for non-fatal heroin
overdose and a 43% decrease in heroin related deaths
[37]; and a 45% decrease in heroin possession/use
offences [38]. This suggests that the decrease in HCV noti-
fications in this group is probably related to the extent of
heroin injection in the community. There are no alterna-
tive explanations for the decrease in notifications, which
was not predicted by mathematical models of the hepati-
tis C epidemic in Australia [39].
The most plausible explanation of the reduction in HCV
notifications among young people is that fewer young
persons were initiating injecting drug use. This suggests
that there has been a reduction in the extent of injecting
drug use and hence probably fewer persons, particularly
younger persons, at risk of contracting BBVIs [9,40]. If this
is the case, any reductions in HCV notification related to
the heroin shortage may be subject to a lag, given the
period between initiation to injecting and HCV serocon-
version. The extent of this lag is unclear, but USA data sug-
gest that many new HCV infections occur within months
of initiating injecting [41]. The proportion of HCV posi-
tive IDUs injecting for less than three years has varied
between 13% and 22% [5,25]. However, given the uncer-
tainly of such a lag, it could not be validly modelled as any
intervention term included, other than the date of the her-
oin shortage, would have been chosen arbitrarily.
Moreover, evidence from the loess smoother showed that
the HCV notifications data series among young people
had levelled off before the shortage. Evidence from this
Number of HIV, Hepatitis B and C notifications, NSW 1997 – 2003 Figure 1
Number of HIV, Hepatitis B and C notifications, NSW 1997 – 2003. NDD and HIV/AIDS databases, Communicable 
Diseases Branch, NSW Health Department.
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same smoother showed that it began to decline some time
after the shortage. This behaviour of the data series is pos-
sibly explained by the shortage.
Despite reports of increased injecting risk, no increase in
other BBVI was reported. Any increase in BBVI risk attrib-
utable to the shortage would most likely have occurred
during the peak period of the shortage, a relatively brief
period of approximately four months [18]. The rate of
HIV infection among IDU in Australia is probably too low
to produce dramatic increases in the number of HIV infec-
tions in that time, even if the risk of infection was
increased [42]. Moreover both HIV and HBV are more eas-
ily and, in Australia, more commonly sexually transmitted
and would therefore be less responsive to any changes in
injecting drug use.
It is important to note that these changes occurred in a set-
ting in which harm reduction measures were readily avail-
able to IDU. It is unclear whether similar trends would be
observed in countries where the prevalence of HIV among
IDU is higher, and where access to harm reduction meas-
ures is more limited. Estimates suggest that IDU in Aus-
tralia would need to share needles/syringes with 31 others
over a year to increase the prevalence of HIV among IDU
in Australia [42]. In contexts where new injecting
equipment is not as readily available as in Australia, or
where the use of cocaine is much more widespread,
changes in heroin availability may have a different effect.
There was also no evidence of increased injection-related
harm, as measured by changes to the number of presenta-
tions at hospitals for injecting-related problems. This was
despite concern about injection-related problems related
to frenetic or risky injecting of benzodiazepines and
cocaine by some IDU [43,44]. It seems most likely that
either these changes occurred among a relatively small
group, and/or that the resulting problems were relatively
minor and treated by general practitioners or other pri-
mary health care services. The number of these infections
attributable to injecting drug use is also likely to be small.
However, a Canadian study found IDU have a high level
Hepatitis C notifications among 15–19 and 20–24 year olds, NSW 1997–2003 Figure 2
Hepatitis C notifications among 15–19 and 20–24 year olds, NSW 1997–2003. NDD and HIV/AIDS databases, Com-
municable Diseases Branch, NSW Health Department.
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of emergency department utilisation, predominantly for
injection related problems, especially soft-tissue infection,
and this is most common among cocaine users and fre-
quent injectors [24].
Limitations
This study has relied on secondary data sources as indirect
measures of the complications of injecting drug use. As
changes at the population level were examined, notifica-
tions were the most appropriate data. As notification of
HIV, HBV and HCV is mandatory in Australia and cases
are typically reported by the testing laboratory, these data
are unlikely to be subject to the reporting bias reported by
others [e.g. [45]]. In Australia, more than 90% of HCV
infections are related to injecting drug use [31], and infec-
tions among 15–19 year olds are most likely to be newly
acquired. Nonetheless, the clear decrease in HCV infec-
tion among young people is not easily explained by any
other hypotheses, and is consistent with other research on
the consequences of the heroin shortage [46].
Several of the conclusions presented here are based on vis-
ual inspection of data series with small numbers, rather
than on statistical analysis. The authors do not believe
that observable effects in these series would be considered
of public health importance even if statistical significance
could be shown, and consider visual inspection suffices in
these instances.
Conclusion
This research has found that following a reduction in her-
oin supply there was no change in HIV or HBV at the pop-
ulation level, but there was an apparent decrease in HCV
infections among those aged 15–19 years. These changes
occurred in a setting with widespread, publicly funded
harm reduction initiatives.
observed and predicted numbers of Hepatitis C Virus notifications in 15–19 year olds, 1997 – 2003 Figure 3
observed and predicted numbers of Hepatitis C Virus notifications in 15–19 year olds, 1997 – 2003. NDD and 
HIV/AIDS databases, Communicable Diseases Branch, NSW Health Department.
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Abbreviations
ARIMA Auto Regressive Integrated Moving Average
BBVI Blood-borne viral infections
ED Emergency department
HCV Hepatitis C virus
HBV Hepatitis B virus
HIV Human immunodeficiency virus
IDU Injecting drug users
NSP Needle and syringe program
NSW New South Wales
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